| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 12, 2024 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
10-Q - TNF Pharmaceuticals, Inc. (0001321834) (Filer)
DEF 14A - TNF Pharmaceuticals, Inc. (0001321834) (Filer)
8-K - TNF Pharmaceuticals, Inc. (0001321834) (Filer)
Prevail Partners, LLC investment priced at more than a 40% premium to market Prevail InfoWorks, Inc. to act as Clinical Research Organization partner; global full service CRO with hundreds of clinical trials over a decade TNF Pharmaceuticals fully funded for clinical trials for next two years TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune and inflammatory conditions, today announced that it has secured a strategic equity investment, priced at a 20% premium to a 30-trading days volume weighted average price (VWAP), from Prevail Partners, LLC, a U.S. investment fund fo
MYMD-1® development to continue through fully funded mid-stage clinical trials Clinical study of MYMD-1 in sarcopenia/frailty met primary endpoints for significantly reducing chronic inflammatory markers with statistical significance MYMD-1 shown to inhibit excessive activity of TNF-alpha to regulate the immuno-metabolic system Company holds FDA-cleared Phase 2 INDs for MYMD-1 in two additional chronic inflammatory conditions, rheumatoid arthritis and Hashimoto's thyroiditis TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory con
SC 13G/A - TNF Pharmaceuticals, Inc. (0001321834) (Subject)